Randomisation of Relapsed and Refractory High-Risk Neuroblastoma Patients Treated with Long-Term Infusion of Anti-GD2 Antibody Dinutuximab Beta with or Without Subcutaneous Interleukin-2, A SIOPEN Study

被引：0
|
作者：
Lode, H. [1 ]
Valteau-Couanet, D. [2 ]
Gray, J. [3 ]
Luksch, R. [4 ]
Wieczorek, A. [5 ]
Castel, V. [6 ]
Ash, S. [7 ]
Owens, C. [8 ]
Laureys, G. [9 ]
Papadakis, V. [10 ]
Garaventa, A. [11 ]
Manzitti, C. [11 ]
Siebert, N. [1 ]
Troschke-Meurer, S. [1 ]
Glogova, E. [12 ]
Poetschger, U. [12 ]
Ladenstein, R. [12 ]
机构：
[1] Univ Med Greifswald, Pediat Hematol & Oncol, Greifswald, Germany
[2] Paris Sud Univ, Gustave Roussy, Children & Adolescent Oncol Dept, Paris, France
[3] Univ Southampton, Pediat Oncol, Southampton, Hants, England
[4] Fdn IRCCS Ist Nazl Tumori, Pediat Oncol, Milan, Italy
[5] Jagiellonian Univ, Coll Med, Pediat Hematol Oncol, Krakow, Poland
[6] Hosp Univ & Politecn La Fe, Pediat Oncol, Valencia, Spain
[7] Tel Aviv Univ, Sackler Fac Med, Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel
[8] Our Ladys Childrens Hosp Crumlin, Pediat Haematol Oncol, Dublin, Ireland
[9] Univ Hosp Ghent, Pediat Oncol, Ghent, Belgium
[10] Agia Sofia Childrens Hosp, Dept Pediat Hematol Oncol, Athens, Greece
[11] IRCCS Ist Giannina Gaslini, Oncol Unit, Genoa, Italy
[12] St Anna Kinderkrebsforsch, CCRI, Vienna, Austria
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP054 SIOP
引用
收藏
页码：S34 / S35
页数：2
相关论文
共 50 条
  • [21] Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
    Mora, Jaume
    Castaneda, Alicia
    Colombo, Maria Cecilia
    Gorostegui, Maite
    Gomez, Fernando
    Mane, Salvador
    Santa-Maria, Vicente
    Garraus, Moira
    Macias, Napoleon
    Perez-Jaume, Sara
    Munoz, Oscar
    Munoz, Juan Pablo
    Barber, Ignasi
    Sunol, Mariona
    CANCERS, 2021, 13 (06) : 1 - 18
  • [22] Early Results from the HR-NBL1/SIOPEN Trial Randomizing Dose-Reduced Subcutaneous Interleukin2 (SCIL2) with Dinutuximab Beta (DB) Long-Term Infusion (LTI) in High-Risk Neuroblastoma Patients
    Ladenstein, R.
    Poetschger, U.
    Valteau-Couanet, D.
    Gray, J.
    Luksch, R.
    Balwierz, W.
    Castel, V.
    Ash, S.
    Beck-Popovic, M.
    Laureys, G.
    Chan, G. Chi Fung
    Ruud, E.
    Vettenranta, K.
    Owens, C.
    Schroeder, H.
    Loibner, H.
    Ambros, P.
    Sarnacki, S.
    Boterberg, T.
    Lode, H.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S31 - S32
  • [23] Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study
    Flaadt, Tim
    Rehm, Jonas
    Simon, Thorsten
    Hero, Barbara
    Ladenstein, Ruth L.
    Lode, Holger N.
    Grabow, Desiree
    Nolte, Sandra
    Crazzolara, Roman
    Greil, Johann
    Ebinger, Martin
    Abele, Michael
    Holzer, Ursula
    Doering, Michaela
    Schulte, Johannes H.
    Bader, Peter
    Schlegel, Paul-Gerhardt
    Eyrich, Matthias
    Lang, Peter
    Klingebiel, Thomas
    Handgretinger, Rupert
    CANCERS, 2025, 17 (01)
  • [24] Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series
    Gartrell, Jessica
    Shulkin, Barry L.
    Helmig, Sara
    Caldwell, Kenneth J.
    Furman, Wayne
    Federico, Sara M.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (05) : E692 - E696
  • [25] The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial
    Mora, Jaume
    Chan, Godfrey C. F.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa K.
    Rubio-San-Simon, Alba
    de las Heras, Blanca Martinez
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [26] Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB).
    Mora, Jaume
    Chan, Godfrey Chi-Fung
    Morgenstern, Daniel A.
    Nysom, Karsten
    Bear, Melissa K.
    Dalby, Lene Worsaae
    Lisby, Steen
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Outcome of Anti-GD2 Immunotherapy in Dutch Patients with High-Risk Neuroblastoma
    Tas, M.
    Dootjes, L.
    Fiocco, M.
    de Krijger, R.
    Dierselhuis, M.
    van Eijkelenburg, N.
    van Grotel, M.
    Kraal, K.
    Peek, A.
    van de Ven, K.
    de Keizer, B.
    Littooij, A.
    Janssens, G.
    Tytgat, G.
    van Noesel, M.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S341 - S342
  • [28] Correlation of killer-cell Ig-like receptor (KIR) haplotypes and Fcy-receptor polymorphisms survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody chi 4.18/CHO.
    Lode, Holger N.
    Troschke-Meurer, Sascha
    Valteau-Couanet, Dominique
    Garaventa, Alberto
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Jensen, Christian
    Eger, Christin
    Juettner, Madlen
    Kietz, Silke
    Ehlert, Karoline
    Janzek, Evelyne
    Loibner, Hans
    Siebert, Nikolai
    Mueller, Ina
    Ladenstein, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Clinical and Behavioral Impact of Serial Digital Education on Anti-Gd2 Therapy for Relapsed/Refractory High-Risk Pediatric Neuroblastoma
    Del Nido, E.
    Ackbarali, T.
    Turell, W.
    Cabral, J.
    Morgenstern, D.
    Modak, S.
    Mora, J.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S217 - S217
  • [30] Naxitamab Humanized anti-GD2 ganglioside monoclonal antibody Treatment of high-risk neuroblastoma
    Rickmann, M.
    DRUGS OF THE FUTURE, 2021, 46 (03) : 197 - 205
12345